All In Biotech

Drug Trial Radar · NCT04143061

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa

Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,328 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,328

Actual

Start

Dec 30, 2019

Primary completion

Jan 28, 2023

Study completion Jan 28, 2023

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Oct 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 12 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This will be a Phase III, modified double-blind (open-label for toddlers in India), randomized, parallel-group, active-controlled, step-wise, multi-center study to compare and describe the immunogenicity and safety of MenACYW conjugate vaccine when administered as a single dose in healthy adults, adolescents, children, and toddlers in India and a modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare and describe the immunogenicity and safety of MenACYW conjugate vaccine when administered as a single dose in healthy adolescents and children in RSA.

Conditions

  • Meningococcal Immunization
  • Healthy Volunteers

Interventions

  • Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccineBiological

    Pharmaceutical form: solution for injection; Route of administration: intramuscular, 0.5 mL

  • Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccineBiological

    Pharmaceutical form: sterile aqueous solution; Route of administration: intramuscular, 0.5 mL

  • Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccineBiological

    Pharmaceutical form: reconstituted solution for injection; Route of administration: intramuscular, 0.5 mL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Group 5 + 7 and Group 6 + 8: Percentage of Participants Who Achieved Antibody Titers ≥1:8 Against Meningococcal Serogroups A, C, Y, and WTime frame: Day 30 (30 days post-vaccination on Day 0)

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 3560002

    Bangalore, India

  • Investigational Site Number : 3560016

    Belagavi, India

  • Investigational Site Number : 3560007

    Chennai, India

  • Investigational Site Number : 3560004

    Hyderabad, India

  • Investigational Site Number : 3560011

    Kolkata, India

  • Investigational Site Number : 3560012

    Mysore, India

  • Investigational Site Number : 3560015

    Odisha, India

  • Investigational Site Number : 3560003

    Pune, India

  • Investigational Site Number : 3560008

    Pune, India

  • Investigational Site Number : 3560010

    Punjab, India

  • Investigational Site Number : 7100004

    Bertsham, South Africa

  • Investigational Site Number : 7100007

    Bloemfontein, South Africa

  • Investigational Site Number : 7100005

    Cape Town, South Africa

  • Investigational Site Number : 7100002

    Cape Town, South Africa

  • Investigational Site Number : 7100001

    Middelburg, South Africa

  • Investigational Site Number : 7100006

    Pretoria, South Africa

  • Investigational Site Number : 7100003

    Soweto, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.